Abstract
In The Lancet Oncology, Walter Heindel and colleagues1 published the findings from the TOSYMA trial, the primary endpoints of which were detection of invasive breast cancer and invasive interval cancer detection rate at 24 months. However, these endpoints have never been validated as proper surrogate outcome measures for breast cancer mortality.2 Screening methods that only increase breast cancer detection and decrease interval cancer detection rates might exacerbate the risk of breast cancer overdiagnosis and have no beneficial effect in decreasing breast cancer mortality.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
